Prostate Cancer Treatment: Shorter Duration High-Intensity Radiation Found To Be Safe

Shorter duration of high-intensity radiation is safe (i.e. no toxicity) in treating low or intermediate-risk prostate cancer, finds a new study.

Short duration high-intensity radiation could be a new alternative to current long duration low dose radiation for treating prostate cancer. The recurrence rate of cancer was found to be similar in both methods. The results of this study are published in the journal of JAMA Network Open.

Men with low or intermediate-risk prostate cancer can safely undergo higher doses of radiation over a significantly shorter period of time and still have the same, successful outcomes as from a much longer course of treatment, according to researchers including one of Indian-origin.

Metastasis Risk in Prostate Cancer Patients can be Predicted Faster: Here's How
A faster and cheaper test called Next-Generation Copy Number Alteration (NG-CNA) assay has been developed, which helps estimate metastasis risk in prostate cancer patients.

‘Men with low or intermediate prostate cancer risk can safely undergo higher doses of radiation over a shorter period of time, as it still has the same, successful outcome that of a longer course of treatment. ’

The study showed that this type of radiation - stereotactic body radiotherapy - is a form of external beam radiation therapy, which reduces the duration of treatment from 45 days to four to five days with no evidence of causing worse toxicity in the long run.

"Most men with low or intermediate-risk prostate cancer undergo conventional radiation, which requires them to come in daily for treatment and takes an average of nine weeks to complete," said lead author Amar Kishan, Assistant Professor at the University of California, Los Angeles, in the US.

"With the improvements being made to modern technology, we have found that using stereotactic body radiotherapy, which has a higher dose of radiation, can safely and effectively be done in a much shorter timeframe without additional toxicity or compromising any chance of a cure," said Kishan.

Spread Awareness about Prostate Cancer and Andropause
Talking about the early detection of prostrate cancer is much needed due to the increasing number of cases across India, says experts.

For the study, the team included 2,142 men with low or intermediate-risk prostate cancer who were treated with stereotactic body radiotherapy. They were followed for a median of 6.9 years.

Nearly, 53 percent of men had low-risk disease, 32 percent had a less aggressive intermediate-risk disease, and 12 percent had a more aggressive form of the intermediate-risk disease.

Antihormone Therapy May Up Heart Failure Risk in Prostate Cancer Patients
Androgen deprivation therapy (ADT), an antihormone therapy increases the risk of developing heart failure in prostate cancer patients, reveals a new study.

In addition, the recurrence rate for men with the low-risk disease was 4.5 percent, 8.6 percent for the less aggressive intermediate-risk, and 14.9 percent for the more aggressive intermediate-risk group, findings published in the journal JAMA Network Open showed.

Overall, the recurrence rate for intermediate-risk disease was 10.2 per cent.

Men with Prostate Cancer Choose Low Survival over Treatments having Side-Effects: Here's Why
Men diagnosed with prostate cancer choose a quality life with low survival odds rather than taking up the treatment and experiencing side-effects.

These are essentially identical to rates following more conventional forms of radiation, which are about 4-5 percent for low-risk disease and 10 percent to 15 percent for the intermediate-risk disease.

This method is both safe and effective and could be a viable treatment option for men with low and intermediate-risk of prostate cancer, the study suggested.

Source-IANS